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Responsibility is the
key word. To as-
sume that all phy-
sicians would act
irresponsibly in
relation to industry
gifts or payments is
inappropriate.n April 2009, an article written by a number of well-respected physicians appeared
in the Journal of the American Medical Association (1). In the article, the authors rec-
ommended sweeping changes in how professional medical associations (PMAs),
uch as the American College of Cardiology (ACC), should interact with pharmaceuti-
al and medical device industries.
Their recommendations included totally removing industry support of PMAs and
olding officers of the PMAs accountable for avoiding any industry support. Their defi-
ition of industry support included participation in Speakers’ Bureaus, industry-funded
linical trials, or investigator-initiated research while serving as an officer of the society.
The authors felt that advertising in medical journals was appropriate and did not re-
uire consideration, and industry grants to academic institutions were also considered
cceptable. However, trainees receiving awards from foundations should not be allowed
o acknowledge or even know the source of their funding, according to the authors.
The authors proposed that the sole source for support of PMAs could only come
rom government or foundation grants and that no society member who had any rela-
ionship with industry could be appointed to a guideline committee. They also sup-
orted full disclosure and transparency regarding funding, and they called on the govern-
ent to fund any clinical trials needed to provide evidence-based guidelines for care.
These recommendations assume that we all are easily influenced by relations with in-
ustry and need to be regulated; there is no comment about trust or virtue as a charac-
eristic of the medical profession. The article implies that all physicians who receive sup-
ort from industry will forever be biased to support the products of the related
harmaceutical or device company. It also implies that industry does not work for the
est interests of patients or the better public good, but only for profit.
aulty Assumptions-Guided Recommendations
he assumptions that led to these conclusions can be challenged on many fronts. First,
o assume that physicians would not be responsible for providing the best care for their
atients after being associated with an industry study or consultation is inappropriate.
he authors cited isolated examples of errant physicians who received large sums of
oney from industry and then promoted their products. They presume that all physi-
ians are represented by these few—that we all have a price. The authors’ assumption
hat the worst behavior is the average behavior of all physicians insults the profession.
We are not to be bribed by a cheap pen or a free lunch. How could we expect pa-
ients to trust us with their lives if they thought we were swayed by a free dinner? On
he other hand, we must act responsibly to eliminate doubt about our level of responsi-
ility for our patients, and we should not accept funds for the purpose of supporting a
ommercial product. The authors’ assumptions imply that physicians as a group are not
esponsible people, yet physicians are among the most responsible professionals.
Any proposal to create proper relations with industry must be based on the assump-ion that we are personally responsible for the best interest of our patients and can work
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President’s Page July 7, 2009:177–9ith industry while maintaining that goal. Responsibility
s the key word. To assume that all physicians would act
rresponsibly in relation to industry gifts or payments is
nappropriate.
ur Goal: To Provide the Best Care
s a physician, my goal—and that of most of my col-
eagues—is to improve overall public health in the U.S.
accomplish this by providing the best care possible to
ndividual patients and groups of patients, by doing re-
earch, by teaching, and by participating in public discus-
ions about health policy whenever possible. I believe
here is a moral right to good health, and that a healthy
ation offers a better chance of long-term survival for a
ivilization.
To improve health, I have set 2 goals: prevention of
isease and treatment of disease. These goals are best
chieved through a well-defined process of research to
nderstand disease and develop new treatments. The pro-
ess begins with basic research, moves through the trans-
ational stage to clinical research, and then continues
hrough application to large populations (clinical trials)
o determine efficacy of a new therapy. The final step
eeds to be a production process that includes large-scale
anufacture and distribution to make the new therapy
vailable.
Funding for these various steps can come from public
r private sources. In most of the developed world, public
unds go primarily toward basic and translational research
nd some clinical research, while private funds generally
upport large clinical trials and manufacture and distribu-
ion of the new therapies. This system, which has evolved
ver several centuries, seems to be highly efficient. Total
ublic funding (i.e., government-run industry) has not
orked in the past, and total private funding reduces the
asic science needed to develop new ideas because much
f basic research provides no evident reward.
Society understands that reward drives innovation, so
xpecting a financial gain from a commercial medical en-
erprise is not wrong. In fact, it is the only way that new
deas will move from the laboratory to the public good.
sing public funds for manufacture and distribution
ould add an enormous burden to government costs and,
ased on past experience, would be unproductive.
One may challenge these points philosophically; how-
ver, this approach, which is the foundation of our eco-
omic system, demonstrates the need for appropriate col-
aboration between industry and the medical community.
any of the advances in medicine in the past century
ould not have been possible without this collaboration.
System That Works
o many examples validate my points. As a learned com-
unity of physicians, surgeons, and clinical and basic sci-
ntists, we hold a critical core of knowledge that should pe disseminated widely for the betterment of our patients.
f one of us has an idea for a new device and needs in-
ustry to help refine its design, fund its development and
anufacture, and establish its value by animal and clinical
tudies, this process should be honored, not condemned.
ill the government fund the development of the next
ew drug? Would the government have funded the devel-
pment and manufacture of an implantable pacemaker?
hese are ventures that require large high-risk invest-
ents, and very few of us could do this on our own.
Governments have not shown an interest in funding
he development of new drugs and devices. Industry raises
he funds, takes the risks, and should reap the rewards for
ts role in creating a better life for our patients. How
ould industry develop new drugs or devices without in-
ut from the clinical and basic scientists among us? Total
eparation between the profession of medicine and the
rug and device industry would cause irreparable harm to
ur patients by the lack of new therapies in the future—
uch more harm than the assumed bias produced by pro-
ibiting industry funding of an education program.
There must be a middle ground. Industry must be able
o call on the expertise of the medical community to de-
elop new drugs and devices. This should not be viewed
s a conflict. Industry should be able to support unbiased
rograms aimed at educating physicians and other health
are providers about the therapies available for the care of
heir patients. Professional societies should be able to re-
eive unconditional educational grants to provide up-to-
ate information to their members on medical therapies.
hysicians should be able to conduct industry-funded
linical trials or consult with industry without being
ainted with an assumption of lifelong misbehavior.
The recent Institute of Medicine report (2) describes a
iddle ground that recognizes the value of collaboration
etween medicine and industry and asks for systems that
llow collaboration but prevent industry influence in edu-
ation, clinical practice, and particularly in production of
uidelines and practice standards.
When Marquis De Tocqueville visited the U.S. in 1830
o learn why our form of democracy worked so well, he
as impressed by the spirit of independence and the en-
repreneurs in the U.S. (3). He also noted a strong sense
f responsibility that made the majority of people feel
hat they had a stake in the public good. New ideas were
eveloped and new products were manufactured because
f the sharing of ideas and the ability to create new en-
erprises. This is the way we achieve new therapies and
ew devices for the future. Let’s not destroy the best of
hat we have in our science and our industry.
The proper relationships should allow us to work with
ndustry and allow our professional societies to receive
ndesignated funds from industry to foster better patient
are. Society should and always has expected professional-
sm (i.e., that we always work for the best interest of our
atients) from the medical profession. We do not need a
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July 7, 2009:177–9 President’s Pageorld of total disengagement; we need a world where
esponsibility and professionalism set the standards of
elationships with industry, and the rules that we create to
upport this behavior are based on the best interest of our
atients. I encourage you to read a statement on this issue
hat reflects the position of several professional organiza-
ions, including the ACC, at http://www.acc.org/PMA-
ointLetterFinal.pdf.
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